Acute Myeloid Leukemia (AML) Treatment Market

Global Acute Myeloid Leukemia (AML) Treatment Market Size (2024 to 2029)

The size of the global acute myeloid leukemia (AML) treatment market was worth USD 2.08 billion in 2023. The global market is estimated to be worth USD 3.77 billion in 2029 and USD 2.3 billion by 2024, registering at a CAGR of 10.44% during the forecast period.

Current Scenario of the Global Acute Myeloid Leukemia (AML) Treatment Market

Acute myeloid leukemia is one of the cancer types that starts in the bone marrow. Bone marrow is where new blood cells are made, which is a small inner part of the bones. AML is started in the bone marrow and quickly spreads into the blood, causing various symptoms to get diagnosed for the cancer disease. Sometimes, AML can be easily spread to other parts like lymph nodes, the liver, the spleen, and the central nervous system. A person diagnosed with AML must be treated effectively, which has a cure if it is diagnosed at an early stage. The innovative launch of various technologies to treat cancer disease in developed and emerging countries is certainly to have a positive impact on the growth rate of the acute myeloid leukemia treatment market.

MARKET DRIVERS

The growing awareness of acute myeloid leukemia is propelling the global market growth.

According to the American Cancer Society, acute myeloid leukemia is one of the most concerning cancer diseases in recent times. The severe concern is that adults are the most affected people in recent years, which is becoming a crucial time to create awareness among people as it can be easily cured if AML is diagnosed at an early stage. According to research by the American Cancer Society, about 28,000 people will be diagnosed with AML in 2023. This survey also reported that more than 11,220 people lost their lives due to AML, where adults are the most common people among them. The growing number of people suffering from cancer diseases is attributed to leveraging the growth rate of the acute myeloid leukemia treatment market.

The continually growing healthcare expenditure is favoring the acute myeloid leukemia market growth.

The demand for high-quality treatment procedures is engraved in the healthcare industry, where the increasing expenditure on the health public is generally ascribed to quality and effective treatment options that substantially leverage the growth rate of the acute myeloid leukemia treatment market. The launch of innovative diagnostics procedures for AML that can diagnose the disease using simple blood tests is also significantly promoting the market's growth rate.

The growing awareness of the availability of various treatment procedures through social media and other communication channels emphasizes the demand for various diagnostic procedures to treat cancer at its early stages. Diagnosing cancer at an early stage can be cured with effective treatment procedures, and a person can lead an everyday life after the treatment with regular follow-ups. Therefore, the rising awareness among people over the availability of different treatment options is anticipated to promote the growth rate of the AML treatment market.

MARKET RESTRAINTS

Acute myeloid leukemia is one of the worst types of cancer diseases, where the mortality rate is very high. Though there are many advanced treatment procedures available to treat AML, the side effects due to these procedures may weaken the immunity system of the patient and lead to death in a few cases as well. AML can become worse if treated or ignored at early stages. The lack of proper knowledge in diagnosing the disease at an early stage, especially among people who live in undeveloped countries, due to lack of complete awareness over the importance of early symptoms and further diagnostics procedures, is attributed to hindering the growth rate of the global market. Government authorities are taking effective measures to tackle the cancer disease that is attributed to the surge in the market’s growth rate.

MARKET OPPORTUNITIES

Adults are more commonly affected by acute myeloid leukemia, and the fatality rate among these people has been very high for a few years. The demand to adopt new techniques in diagnosing the disease and further treatment procedures is eventually rising, and this is subject to increasing growth opportunities in the coming years. The trend towards adopting a sedentary lifestyle due to the hectic work schedules in both men and women is attributed to an increasing number of diseases. Lack of physical activity and eating more junk food items among people, especially in urban areas, due to lack of time increases the risk of various chronic diseases. Smoking can severely cause the AML to progress in the blood without time, which subsequently affects a high number of people. AML is a rare and dangerous cancer that occurs in almost 20,000 patients per year only in the US, according to the Leukemia & Lymphoma Society. On the other side, children are also highly affected by this disease. Every year, around 650 children are diagnosed with AML, which is raising concern about the launch of effective treatment procedures to save lives.

MARKET CHALLENGES

High costs associated with the treatment procedures of AML are a significant challenge for global market growth.

The treatment and diagnostic procedures of AML are highly expensive, which is a huge burden for the common people to avail of these procedures. The lack of government support for health insurance in many countries due to the rising economic crisis is a great challenge for key market players. Introducing new treatment procedures at affordable prices is not an easy task for top companies, and it is slightly degrading the growth rate of the acute myeloid leukemia (AML) treatment market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Acute Myeloid Leukemia (AML) Treatment Market Analysis By Disease Type

The myeloblastic leukemia segment is ruling with the dominant share of the acute myeloid leukemia (AML) treatment market. The rising popularity of the availability of various treatment procedures is likely to fuel the growth rate of the market in the coming years. The prominence for the varied and most effective treatment procedure is eventually increasing with the rising number of people suffering from cancer disease globally. The myelomonocytic leukemia segment is expected to reach the highest CAGR by the end of the forecast period. The launch of innovative diagnostic procedures is likely to surge the growth rate of the segment in the coming years.

Global Acute Myeloid Leukemia (AML) Treatment Market Analysis By Treatment Type

The chemotherapy segment holds the largest share of the acute myeloid leukemia (AML) treatment market. Chemotherapy is one of the finest and most effective treatment procedures to kill cancer cells. It is a primary treatment procedure for any kind of cancer that has a high chance of cure. It is effective in curing the cancer disease completely or can stop the cells or slow the growth of new cancer cells. Targeted therapy is gaining much traction these days as the rising vision to have effective treatment procedures with minimal side effects to lead a normal lifestyle post-treatment. The advanced technology is completely responsible for launching popular treatment procedures for acute myeloid leukemia, where the demand for the targeted therapy is notably increasing with the launch of innovative drugs that specifically target the cancer cells, which is different from the chemotherapy procedure.

Global Acute Myeloid Leukemia (AML) Treatment Market Analysis By Route of Administration

The parenteral segment is inclined to have prominent growth opportunities during the forecast period. The parenteral route of administration segment is ascribed to effectively treating the cancer cells, which is an initial treatment procedure once it is diagnosed. The oral segment has substantially held the fastest growth rate in recent years. The rising number of people suffering from acute myeloid leukemia need to focus on continuing the medication for a long period even after chemotherapy, which is accelerating the growth rate of the oral route of administration segment.

Global Acute Myeloid Leukemia (AML) Treatment Market Analysis By End-Use

The hospital and clinics segment dominated the market in 2023 and is expected to rule the market with the highest share of the global acute myeloid leukemia (AML) treatment market during the forecast period. The number of hospitals that treat cancer patients is eventually increasing every year to meet the demand of the growing population that is leveling up the market’s growth rate.

REGIONAL ANALYSIS

North America held the leading share of the acute myeloid leukemia (AML) treatment market in 2023.

Developed countries like the US and Canada pose huge growth opportunities for the market with the presence of highly advanced medical infrastructure with various technologies available to treat cancer diseases. The presence of the top companies and frequent launches of innovative technological developments in the medical sector is set to promote the growth rate of the market in North America. According to the National Library of Medicine, most elderly people of age above 60 years are highly affected by acute myeloid leukemia. The rising number of AML cases is a rising burden to launch new and innovative procedures to reduce the mortality rate in this region, which is ascribed to bolstering the growth rate of the market.

Asia-Pacific is gearing up to hold the fastest CAGR during the forecast period.

Asia Pacific region is huge and populous, with the presence of emerging countries like India and China. There is an increasing number of elderly population in these countries during the forecast period. According to the National Institutes of Health, 22% of the total population will be elderly people by the end of 2030, which is causing huge demand to improve the healthcare infrastructure with the most advanced technologies.

Europe is anticipated to account for a substantial share of the global market during the forecast period.

Europe is deemed to have a prominent share of the acute myeloid leukemia (AML) treatment market next to North America. Acute myeloid leukemia is becoming the most common disease in Europe, which is ascribed to leveraging the need to launch new treatment procedures in countries like the UK, Germany, Italy, France, and Spain.

KEY PLAYERS IN THE GLOBAL ACUTE MYELOID LEUKEMIA (AML) TREATMENT MARKET

Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals plc, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Partner Therapeutics, Inc., Pfizer Inc. and Rigel Pharmaceuticals, Inc. are a few of the leading players in the global acute myeloid leukemia treatment market.

RECENT HAPPENINGS IN THE GLOBAL MARKET

• In 2024, Quizartinib (Vanflyta), developed by Daiichi Sankyo Company, was authorized by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). This is an oral route of administration with the combination of chemotherapy, which is effective in treating AML. This drug is prescribed according to the healthcare provider and can lower the abnormal growth of the cancer cells in the bone marrow.

DETAILED SEGMENTATION OF THE GLOBAL ACUTE MYELOID LEUKEMIA (AML) TREATMENT MARKET INCLUDED IN THIS REPORT

This research report on the global acute myeloid leukemia treatment market has been segmented and sub-segmented by disease type, treatment type, route of administration, end use and region.

By Disease Type

• Myeloblastic Leukemia 
• Myelomonocytic Leukemia
• Promyelocytic Leukemia
• Monocytic Leukemia

By Treatment Type

• Chemotherapy
  • Anti-Metabolites
  • Alkylating Agents
  • Anthracycline Drugs
  • Other Chemotherapy Types 
• Targeted Therapy
• Immunotherapy
• Other Treatment Types

By Route Of Administration

• Parenteral
• Oral

By End-User

• Hospitals & Clinics
• Specialty Centers
• Homecare Settings
• Ambulatory Care Centers

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa